GAM Holding AG Makes New $588,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GAM Holding AG purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, Holdings Channel.com reports. The firm purchased 6,575 shares of the medical equipment provider’s stock, valued at approximately $588,000.

Other large investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its stake in Lantheus by 60.0% in the fourth quarter. Venturi Wealth Management LLC now owns 3,625 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 1,359 shares during the last quarter. Sanctuary Advisors LLC grew its position in shares of Lantheus by 58.5% in the 4th quarter. Sanctuary Advisors LLC now owns 18,042 shares of the medical equipment provider’s stock worth $1,674,000 after buying an additional 6,656 shares during the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after acquiring an additional 115 shares in the last quarter. Rhumbline Advisers lifted its position in Lantheus by 1.5% during the fourth quarter. Rhumbline Advisers now owns 212,673 shares of the medical equipment provider’s stock valued at $19,026,000 after acquiring an additional 3,136 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in Lantheus by 31.7% in the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider’s stock valued at $6,888,000 after acquiring an additional 18,524 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Up 4.5 %

Lantheus stock opened at $83.53 on Wednesday. The stock has a 50-day moving average price of $91.17 and a 200 day moving average price of $97.53. The company has a market capitalization of $5.81 billion, a price-to-earnings ratio of 13.90 and a beta of 0.44. Lantheus Holdings, Inc. has a 52 week low of $56.06 and a 52 week high of $126.89.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.